Advances in the treatment of Crohn’s disease
- 1 May 2004
- journal article
- review article
- Published by Elsevier in Gastroenterology
- Vol. 126 (6) , 1574-1581
- https://doi.org/10.1053/j.gastro.2004.01.062
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD)Gastroenterology, 2003
- Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trialGastroenterology, 2002
- Budesonide Cir Capsules (Once Or Twice Daily Divided-Dose) in Active Crohn's Disease: A Randomized Placebo-Controlled Study in The United StatesAmerican Journal of Gastroenterology, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trialGastroenterology, 2001
- A Comparison of Budesonide and Mesalamine for Active Crohn's DiseaseNew England Journal of Medicine, 1998
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Oral budesonide is as effective as oral prednisolone in active Crohn’s diseaseGut, 1997
- A Comparison of Budesonide with Prednisolone for Active Crohn's DiseaseNew England Journal of Medicine, 1994
- Oral Budesonide for Active Crohn's DiseaseNew England Journal of Medicine, 1994